Although TRAIL has been shown to be effective for some brain tumor types [5]–[12], [21] and UW426-type MB in this study, it is well known that established tumor lines have varying resistance/sensitivity with about 50% of lines being resistant to TRAIL [46], [47]. Here, TNFSF10 is linked to neoplasm.